Table 3 Survey results on biologic treatment of CRSwNP.
Total cohort N = 50 | Hospital-based n = 25 | Private practice n = 25 | p-value | |
|---|---|---|---|---|
Known biologics | ||||
Dupilumab | 30 (60%) | 17 (68%) | 13 (52%) | 0.387 |
Mepolizumab | 14 (28%) | 6 (24%) | 8 (32%) | 0.757 |
Omalizumab | 9 (18%) | 3 (12%) | 6 (24%) | 0.463 |
Reasons to initiate biologic treatment | ||||
Reduction of the need for FESS | 48 (96%) | 25 (100%) | 23 (92%) | 0.490 |
Improvement of smell function | 30 (60%) | 15 (60%) | 15 (60%) | 1.000 |
Reduction of SCS usage | 28 (56%) | 12 (48%) | 16 (64%) | 0.393 |
High risk for surgery | 28 (56%) | 11 (44%) | 17 (68%) | 0.154 |
Insufficient symptom control | 10 (20%) | 8 (32%) | 2 (8%) | 0.074 |
Accordance to guidelines | 6 (12%) | 4 (16%) | 2 (8%) | 0.667 |
Preferred dosing interval | 0.598 | |||
2 weeks | 12 (24%) | 6 (24%) | 6 (24%) | |
4 weeks | 37 (74%) | 19 (76% | 18 (72%) | |
Patients’ preference | 1 (2%) | 0% | 1 (2%) | |
Assessed criteria for biologic effectiveness | ||||
Improved sense of smell | 35 (70%) | 14 (56%) | 21 (84%) | 0.062 |
Improved quality of life (SNOT-22) | 14 (28%) | 14 (28%) | 14 (28%) | 1.000 |
Reduction of nasal polyp score | 29 (58%) | 16 (64%) | 13 (52%) | 0.567 |
Reduction of nasal congestion score | 15 (30%) | 10 (40%) | 5 (20%) | 0.217 |
No need of SCS | 1 (2%) | 1 (4%) | 0 (%) | 0.312 |
No need of FESS | 2 (4%) | 1 (4%) | 1 (4%) | 1.000 |
Improved comorbidities | 1 (2%) | 0 | 1 (2%) | 0.658 |
